Betrixaban compared with warfarin in patients with atrial fibrillation: results of a phase 2, randomized, dose-ranging study (Explore-Xa)

AIMS: Patients with atrial fibrillation (AF) are at increased risk of stroke. Betrixaban is a novel oral factor Xa inhibitor administered once daily, mostly excreted unchanged in the bile and with low (17%) renal excretion. METHODS AND RESULTS: Patients with AF and more than one risk factor for stro...

Descripción completa

Detalles Bibliográficos
Autores principales: Connolly, Stuart J., Eikelboom, John, Dorian, Paul, Hohnloser, Stefan H., Gretler, Daniel D., Sinha, Uma, Ezekowitz, Michael D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2013
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659305/
https://www.ncbi.nlm.nih.gov/pubmed/23487517
http://dx.doi.org/10.1093/eurheartj/eht039

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3659305/
https://www.ncbi.nlm.nih.gov/pubmed/23487517
http://dx.doi.org/10.1093/eurheartj/eht039

Ejemplares similares